Entering text into the input field will update the search result below

Altimmune: Suppressed, Immature, Or Dormant?

Dec. 05, 2018 3:22 PM ETAltimmune, Inc. (ALT)AZN, EBS, GSK, NEOS, NVS, SNY15 Comments


  • With peak flu season approaching, biotech investors often search for the next best vaccine. I believe NasoVAX is a contender.
  • A rAd primer- I provide vital information on recombinant adenovirus vector vaccines, and how they relate to NasoVAX.
  • A new CEO: The former Neos CEO is now steering the ship at Altimmune. Was this the right move? Investors need to understand his views for the company.
  • The flu vaccine market is strong, with room for new products. I look at several valuation scenarios.
  • When developing a position in a low-float playground, look at the charts to confirm the right price.

2018 has been a volatile year for Altimmune (NASDAQ:ALT) from start to finish. The company experienced mixed results in clinical trials as well as changes management positions. Unfortunately, the share price has taken the brunt of the losses and has gained little from the wins. After a reverse split in September, the stock went parabolic due to a low float run; then it crashed due to subsequent share offerings. Currently, the share price appears to have stabilized around the $3.00 mark and the chart appears to be ready for a move. However, it is the seasonal flu that could inject some momentum back into this stock. I aim to prove that this sub $30M market cap biotech is severely undervalued and should be on your speculative watch list.



Company Overview

Altimmune is a clinical stage immunotherapeutic biotech company developing two ground-breaking vaccine delivery platforms, RespirVec and Densigen. Altimmune is capable of designing and developing immunotherapeutic products intended to address a wide range of disease indications including acute respiratory infections, chronic viral infections, and cancer. Ultimately, the company intends to create products that have distinct advantages over current products.


The company's leading contender, NasoVAX, is an intranasally administered influenza vaccine. NasoVAX uses an adenovector to improve the influenza antigen inside the target cell, thus theoretically encouraging a more systemic and rapid immune response compared to traditional influenza vaccines.

HepTcell is being developed as an immunotherapy for patients chronically infected with the hepatitis B virus, or HBV. HepTcell's goal is to deliver a "functional cure" for HPV.

SparVax-L is a potential two dose Anthrax vaccine being developed in collaboration with the National Institute of Allergy and Infectious Diseases.

Moreover, the company is developing another Anthrax vaccine named NasoShield, a first-in-class product intended to provide rapid, stable protection after a single intranasal administration.

This article was written by

Biologics profile picture
Diagnosing the market to compound capital in the healthcare sector.

After years of working in the medical field, I have developed a passion for biotech and lifesaving therapies. Now, I am a full-time healthcare investor who is in search of the next breakthrough therapy, device, or pharmaceutical. My trade focus is around catalysts and potential acquisitions. In addition, I provide a marketplace service, Compounding Healthcare through Seeking Alpha.

Analyst’s Disclosure: I/we have no positions in any stocks mentioned, but may initiate a long position in ALT over the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.